Beijing Sinotau International Pharmaceutical Technology (Sinotau) has secured over 1.1 billion yuan ($151.8 million) in a new funding round to advance the R&D and clinical trials of its radiopharmaceutical pipeline, the firm announced on Monday.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
